AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival Read more
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial Read more
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 bn sales by 2029: GlobalData Read more